Table 1 Demographic and baseline characteristics of study subjects (mITT population).
Characteristic N (%)/Median [range] | PCD (N = 62) | PD (N = 60) |
|---|---|---|
Age | 68.5 [47–88] | 67.2 [48–85] |
i. ≤60 years | 15 (24.2) | 14 (23.3) |
ii. >60 years | 47 (75.8) | 46 (76.7) |
Gender | ||
i. Male | 35 (56.5) | 29 (48.3) |
ii. Female | ||
Ethnicity | ||
i. Korean | 25 (40.3) | 26 (43.3) |
ii. Chinese | 24 (38.7) | 20 (33.3) |
iii. Japanese | 6 (9.7) | 5 (8.3) |
iv. Malay | 3 (4.8) | 5 (8.3) |
v. Indian | 2 (3.2) | 1 (1.7) |
vi. Others | 2 (3.2) | 3 (5.0) |
ISS Stage I or II | 45 (72.6) | 45 (75) |
ISS Stage III | 17 (27.4) | 15 (25) |
ECOG performance score | ||
i. 0 or 1 | 55 (88.7) | 50 (83.3) |
ii. 2 | 7 (11.3) | 8 (13.3) |
iii. Missing | 0 | 2 (3.3) |
Genetics | ||
i. Standard risk | 14 (22.6) | 9 (15) |
ii. High risk | 8 (12.9) | 20 (33.3) |
iii. Missing/Test not done | 40 (64.5) | 31 (51.7) |
# High risk genetics were defined as 17p deletion, t(4;14), t(14;16), and 1q gain. | ||
Number of lines of prior treatment | 3.0 [1–6] | 3.0 [1–6] |
Previously received therapies | ||
i. Bortezomib | 47 (75.8) | 46 (76.7) |
ii. Lenalidomide | 61 (98.4) | 60 (100) |
iii. Carfilzomib | 24 (38.7) | 18 (30) |
iv. Ixazomib | 7 (11.3) | 8 (13.3) |
v. Thalidomide | 34 (54.8) | 28 (46.7) |
vi. Cyclophosphamide | 29 (46.8) | 19 (31.7) |
vii. Daratumumab | 17 (27.4) | 9 (15.0) |
Prior autologous transplant | 27 (43.5) | 24 (40) |
